{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:59:50Z","timestamp":1794113990896,"version":"4.8.0"},"reference-count":90,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Dermatitis herpetiformis (DH), Duhring disease, is caused by gluten sensitivity and affects 11.2 to 75.3 per 100,000 people in the United States and Europe with an incidence of 0.4 to 3.5 per 100,000 people per year. DH is characterized by a symmetrical blistering rash on the extensor surfaces with severe pruritus. The diagnosis continues to be made primarily by pathognomonic findings on histopathology, especially direct immunofluorescence (DIF). Recently, anti-epidermal transglutaminase (TG3) antibodies have shown to be a primary diagnostic serology, while anti-tissue transglutaminase (TG2) and other autoantibodies may be used to support the diagnosis and for disease monitoring. Newly diagnosed patients with DH should be screened and assessed for associated diseases and complications. A gluten-free diet (GFD) and dapsone are still mainstays of treatment, but other medications may be necessary for recalcitrant cases. Well-controlled DH patients, managed by a dermatologist, a gastroenterologist, and a dietician, have an excellent prognosis. Our review comprehensively details the current diagnostic methods, as well as methods used to monitor its disease course. We also describe both the traditional and novel management options reported in the literature.<\/jats:p>","DOI":"10.3390\/medicina57080843","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T08:44:45Z","timestamp":1629449085000},"page":"843","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management"],"prefix":"10.3390","volume":"57","author":[{"given":"Christopher N.","family":"Nguyen","sequence":"first","affiliation":[{"name":"School of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jaad.2010.09.777","article-title":"Dermatitis herpetiformis, Part I. Epidemiology, pathogenesis, and clinical presentation","volume":"64","author":"Bolotin","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2133.2011.10385.x","article-title":"Prevalence and incidence of dermatitis herpetiformis: A 40-year prospective study from Finland","volume":"165","author":"Salmi","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/08830185.2018.1533008","article-title":"An update on the cutaneous manifestations of coeliac disease and non-coeliac gluten sensitivity","volume":"37","author":"Graziano","year":"2018","journal-title":"Int. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cgh.2017.06.037","article-title":"Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/003655202753387356","article-title":"First-degree relatives are frequently affected in coeliac disease and dermatitis herpetiformis","volume":"37","author":"Hervonen","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrgastro.2015.131","article-title":"Extraintestinal manifestations of coeliac disease","volume":"12","author":"Leffler","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Reunala, T., Salmi, T.T., Hervonen, K., Kaukinen, K., and Collin, P. (2018). Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease. Nutrients, 10.","DOI":"10.3390\/nu10050602"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239691","DOI":"10.1155\/2012\/239691","article-title":"Dermatitis herpetiformis: From the genetics to the development of skin lesions","volume":"2012","author":"Bonciani","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fimmu.2019.01290","article-title":"Dermatitis Herpetiformis: Novel Perspectives","volume":"10","author":"Antiga","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/1203475418795818","article-title":"Facial Involvement in Dermatitis Herpetiformis: A Case Report and Review of the Literature","volume":"23","author":"Cinats","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"adv00056","DOI":"10.2340\/00015555-3401","article-title":"Current Concepts of Dermatitis Herpetiformis","volume":"100","author":"Salmi","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000347108","article-title":"Acral purpura as leading clinical manifestation of dermatitis herpetiformis: Report of two adult cases with a review of the literature","volume":"227","author":"Tu","year":"2013","journal-title":"Dermatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1525-1470.2011.01401.x","article-title":"Dermatitis herpetiformis presenting as digital petechiae","volume":"29","author":"Heinlin","year":"2012","journal-title":"Pediatr. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archdermatol.2011.293","article-title":"Leukocytoclastic vasculitis as the presenting feature of dermatitis herpetiformis","volume":"147","author":"Naylor","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1365-2133.2003.05660.x","article-title":"Dermatitis herpetiformis Duhring with palmoplantar keratosis","volume":"149","author":"Ohshima","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.0736-8046.2004.21509.x","article-title":"Dermatitis herpetiformis presenting as chronic urticaria","volume":"21","author":"Powell","year":"2004","journal-title":"Pediatr. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2230.2005.02009.x","article-title":"Atypical dermatitis herpetiformis: A Japanese case that presented with initial lesions mimicking prurigo pigmentosa","volume":"31","author":"Saito","year":"2006","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/07853890.2016.1222450","article-title":"Dermatitis herpetiformis: A cutaneous manifestation of coeliac disease","volume":"49","author":"Collin","year":"2017","journal-title":"Ann. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/ijd.13725","article-title":"Trichoscopy\u2014A useful tool in the preliminary differential diagnosis of autoimmune bullous diseases","volume":"56","author":"Rudnicka","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/jdv.17183","article-title":"S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"35","author":"Antiga","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CCID.S69127","article-title":"The diagnosis and treatment of dermatitis herpetiformis","volume":"13","author":"Antiga","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.det.2011.03.019","article-title":"An exception within the group of autoimmune blistering diseases: Dermatitis herpetiformis, the gluten-sensitive dermopathy","volume":"29","year":"2011","journal-title":"Dermatol. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1590\/abd1806-4841.2019940208","article-title":"Consensus on the treatment of autoimmune bullous dermatoses: Dermatitis herpetiformis and linear IgA bullous dermatosis\u2014Brazilian Society of Dermatology","volume":"94","author":"Vale","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/2050640619844125","article-title":"European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders","volume":"7","author":"Volta","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-2036.2012.04998.x","article-title":"The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: A cohort study","volume":"35","author":"Grainge","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.dld.2006.03.002","article-title":"Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study","volume":"38","author":"Viljamaa","year":"2006","journal-title":"Dig. Liver Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/B978-0-7020-4087-0.00041-3","article-title":"Gluten-related neurologic dysfunction","volume":"120","author":"Hadjivassiliou","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jnnp.72.2.259","article-title":"Dermatitis herpetiformis and neurological dysfunction","volume":"72","author":"Wills","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2340\/00015555-0220","article-title":"Dermatitis herpetiformis presenting as ataxia in a child","volume":"87","author":"Helsing","year":"2007","journal-title":"Acta Derm. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/jamaneurol.2013.6277","article-title":"Transverse myelitis associated with an itchy rash and hyperckemia: Neuromyelitis optica associated with dermatitis herpetiformis","volume":"71","author":"Iyer","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jid.2020.05.091","article-title":"Atopic Dermatitis Is Associated with Dermatitis Herpetiformis and Celiac Disease in Children","volume":"141","author":"Kauppi","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jid.2018.10.010","article-title":"Dermatitis Herpetiformis and Celiac Disease Increase the Risk of Bullous Pemphigoid","volume":"139","author":"Varpuluoma","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jaad.2010.09.776","article-title":"Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis","volume":"64","author":"Bolotin","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.20011299","article-title":"Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis","volume":"195","author":"Merkl","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D3274053166","article-title":"Evaluation of IgA epidermal transglutaminase ELISA in suspected dermatitis herpetiformis patients","volume":"27","author":"Betz","year":"2021","journal-title":"Dermatol. Online J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/jid.2009.142","article-title":"IgA antiepidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease","volume":"129","author":"Jaskowski","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1468-3083.2012.04586.x","article-title":"IgA anti-epidermal transglutaminase autoantibodies: A sensible and sensitive marker for diagnosis of dermatitis herpetiformis in adult patients","volume":"27","author":"Borroni","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.dld.2016.03.003","article-title":"Serum transglutaminase 3 antibodies correlate with age at celiac disease diagnosis","volume":"48","author":"Salmi","year":"2016","journal-title":"Dig. Liver Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"967974","DOI":"10.1155\/2012\/967974","article-title":"Newly described clinical and immunopathological feature of dermatitis herpetiformis","volume":"2012","author":"Bonciolini","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cca.2012.10.051","article-title":"Neo-epitope tissue transglutaminase autoantibodies as a biomarker of the gluten sensitive skin disease\u2014Dermatitis herpetiformis","volume":"415","author":"Lytton","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/j.jaad.2005.06.033","article-title":"Dermatitis herpetiformis and partial IgA deficiency","volume":"54","author":"Samolitis","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1111\/jdv.16822","article-title":"A novel quantitative ELISA as accurate and reproducible tool to detect epidermal transglutaminase antibodies in patients with Dermatitis Herpetiformis","volume":"35","author":"Ziberna","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gornowicz-Porowska, J., Seraszek-Jaros, A., Ja\u0142owska, M., Bowszyc-Dmochowska, M., Kaczmarek, E., and Dmochowski, M. (2021). Evaluation of a Bi-Analyte Immunoblot as a Useful Tool for Diagnosing Dermatitis Herpetiformis. Diagnostics, 11.","DOI":"10.3390\/diagnostics11081414"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hadjivassiliou, M., Reunala, T., Hervonen, K., Aeschlimann, P., and Aeschlimann, D. (2020). TG6 Auto-Antibodies in Dermatitis Herpetiformis. Nutrients, 12.","DOI":"10.3390\/nu12092884"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaad.2011.02.025","article-title":"Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides","volume":"66","author":"Kasperkiewicz","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_46","first-page":"8980534","article-title":"Correlation between IL36\u03b1 and IL17 and Activity of the Disease in Selected Autoimmune Blistering Diseases","volume":"2017","author":"Ociepa","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1468-3083.2009.03188.x","article-title":"Guidelines for the diagnosis and treatment of dermatitis herpetiformis","volume":"23","author":"Caproni","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archderm.1996.03890320060010","article-title":"Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis","volume":"132","author":"Zone","year":"1996","journal-title":"Arch. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2133.1969.tb16024.x","article-title":"Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. An immunofluorescent study","volume":"81","year":"1969","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1600-0560.2009.01472.x","article-title":"Fibrillar IgA deposition in dermatitis herpetiformis--an underreported pattern with potential clinical significance","volume":"37","author":"Ko","year":"2010","journal-title":"J. Cutan. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"562168","DOI":"10.1155\/2012\/562168","article-title":"Distinct characteristics in Japanese dermatitis herpetiformis: A review of all 91 Japanese patients over the last 35 years","volume":"2012","author":"Ohata","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-4632.2011.04909.x","article-title":"Negative direct immunofluorescence and nonspecific histology do not exclude the diagnosis of dermatitis herpetiformis Duhring","volume":"52","author":"Huber","year":"2013","journal-title":"Int. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2133.1961.tb14442.x","article-title":"The histological diagnosis of dermatitis herpetiformis, bullous pemphigoid and erythema multifore","volume":"73","author":"Pierard","year":"1961","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5070\/D32KW0R6BH","article-title":"Dermatitis herpetiformis: Potential for confusion with linear IgA bullous dermatosis on direct immunofluorescence","volume":"14","author":"Van","year":"2008","journal-title":"Dermatol. Online J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00000372-200208000-00003","article-title":"Characterization of a subgroup of patients with dermatitis herpetiformis with nonclassical histologic features","volume":"24","author":"Warren","year":"2002","journal-title":"Am. J. Dermatopathol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mansikka, E., Hervonen, K., Kaukinen, K., Collin, P., Huhtala, H., Reunala, T., and Salmi, T. (2018). Prognosis of Dermatitis Herpetiformis Patients with and without Villous Atrophy at Diagnosis. Nutrients, 10.","DOI":"10.3390\/nu10050641"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MCG.0000000000000533","article-title":"The decreasing prevalence of severe villous atrophy in Dermatitis herpetiformis: A 45-year experience in 393 patients","volume":"51","author":"Mansikka","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_58","first-page":"6307035","article-title":"Female Patients with Dermatitis Herpetiformis Show a Reduced Diagnostic Delay and Have Higher Sensitivity Rates at Autoantibody Testing for Celiac Disease","volume":"29","author":"Antiga","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/bjd.13387","article-title":"IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis: A significant but not complete response to a gluten-free diet treatment","volume":"172","author":"Reunala","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Alakoski, A., Hervonen, K., Mansikka, E., Reunala, T., Kaukinen, K., Kivel\u00e4, L., Laurikka, P., Huhtala, H., Kurppa, K., and Salmi, T. (2020). The Long-Term Safety and Quality of Life Effects of Oats in Dermatitis Herpetiformis. Nutrients, 12.","DOI":"10.3390\/nu12041060"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2133.1994.tb08557.x","article-title":"25 years\u2019 experience of a gluten-free diet in the treatment of dermatitis herpetiformis","volume":"131","author":"Garioch","year":"1994","journal-title":"Br. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5070\/D32622H9K7","article-title":"Dermatitis herpetiformis and gluten-free diet","volume":"11","author":"Turchin","year":"2005","journal-title":"Dermatol. Online J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1365-2133.2003.05579.x","article-title":"Long-term remission in patients with dermatitis herpetiformis on a normal diet","volume":"149","author":"Bardella","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archdermatol.2010.336","article-title":"Remission in dermatitis herpetiformis: A cohort study","volume":"147","author":"Paek","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.jid.2019.03.1150","article-title":"Gluten Challenge Induces Skin and Small Bowel Relapse in Long-Term Gluten-Free Diet-Treated Dermatitis Herpetiformis","volume":"39","author":"Mansikka","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2340\/00015555-2184","article-title":"Dermatitis Herpetiformis Refractory to Gluten-free Dietary Treatment","volume":"96","author":"Hervonen","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulfones in dermatology. Overview and update","volume":"45","author":"Zhu","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.det.2007.02.001","article-title":"Suggested guidelines for patient monitoring: Hepatic and hematologic toxicity attributable to systemic dermatologic drugs","volume":"25","author":"Wolverton","year":"2007","journal-title":"Dermatol. Clin."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/09540105.2021.1918067","article-title":"Dermatitis herpetiformis Duhring\u2014Evaluation of disease severity and tissue transglutaminase levels in 122 patients on dapsone therapy","volume":"32","author":"Jarmila","year":"2021","journal-title":"Food Agric. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0140-6736(73)91539-0","article-title":"Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal","volume":"1","author":"Fry","year":"1973","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2133.1977.tb14122.x","article-title":"Gluten-free diet in dermatitis herpetiformis. I. Clinical response of skin lesions in 81 patients","volume":"97","author":"Reunala","year":"1977","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"adv00443","DOI":"10.2340\/00015555-3795","article-title":"Anaemia in Dermatitis Herpetiformis: Prevalence and Associated Factors at Diagnosis and One-year Follow-up","volume":"29","author":"Alakoski","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40257-020-00584-2","article-title":"Dermatitis Herpetiformis: An Update on Diagnosis and Management","volume":"22","author":"Reunala","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_74","first-page":"958","article-title":"Dapsone-induced methemoglobinemia: Case of the blue lady","volume":"59","author":"Burke","year":"2013","journal-title":"Can. Fam. Physician"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1399-6576.1998.tb05173.x","article-title":"Methemoglobinemia induced by methylene blue perturbation during laparoscopy","volume":"42","author":"Bilgin","year":"1998","journal-title":"Acta Anaesthesiol. Scand."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3315\/jdcr.2012.1124","article-title":"Letter to the editor: Application of dapsone 5% gel in a patient with dermatitis herpetiformis","volume":"6","author":"Handler","year":"2012","journal-title":"J. Dermatol. Case Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1440-0960.2005.00152.x","article-title":"Sulfasalazine and dermatitis herpetiformis","volume":"46","author":"Willsteed","year":"2005","journal-title":"Australas. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2133.1989.tb08218.x","article-title":"Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid","volume":"121","author":"McFadden","year":"1989","journal-title":"Br. J. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1111\/ijd.13542","article-title":"Dapsone and sulfasalazine combination therapy in dermatitis herpetiformis","volume":"56","author":"Bevans","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archderm.1980.01640360047016","article-title":"Treatment of dermatites herpetiformis with colchicine","volume":"116","author":"Silvers","year":"1980","journal-title":"Arch. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0190-9622(08)80657-3","article-title":"Efficacy of cyclosporine in two patients with dermatitis herpetiformis resistant to conventional therapy","volume":"28","author":"Stenveld","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1365-2230.2000.00615.x","article-title":"Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide","volume":"25","author":"Shah","year":"2000","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0190-9622(08)81769-0","article-title":"Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone","volume":"28","author":"Zemtsov","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2133.1963.tb15687.x","article-title":"The treatment of dermatitis herpetiformis with heparin","volume":"75","author":"Alexander","year":"1963","journal-title":"Br. J. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/jid.1950.31","article-title":"Nicotinic acid therapy of dermatitis herpetiformis","volume":"14","author":"Johnson","year":"1950","journal-title":"J. Investig. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jamadermatol.2016.4676","article-title":"Rituximab Treatment for Recalcitrant Dermatitis Herpetiformis","volume":"153","author":"Albers","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_87","first-page":"88","article-title":"Dermatitis herpetiformis in a patient receiving infliximab for ankylosing spondylitis","volume":"18","author":"Marakli","year":"2008","journal-title":"Eur. J. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jdermsci.2017.04.008","article-title":"Serum levels and tissue expression of interleukin-31 in dermatitis herpetiformis and bullous pemphigoid","volume":"87","author":"Bonciani","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40257-015-0149-1","article-title":"Quality of life and gastrointestinal symptoms in long-term treated Dermatitis herpetiformis patients: A cross-sectional study in Finland","volume":"16","author":"Pasternack","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1365-2133.2012.11105.x","article-title":"Reduced mortality in dermatitis herpetiformis: A population-based study of 476 patients","volume":"167","author":"Hervonen","year":"2012","journal-title":"Br. J. Dermatol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/8\/843\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:47:45Z","timestamp":1760165265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/8\/843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":90,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["medicina57080843"],"URL":"https:\/\/doi.org\/10.3390\/medicina57080843","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}